[Correspondence] CALLA trial: immunotherapy in locally advanced cervical cancer

Bradley J Monk and colleagues reported the results of a randomised controlled trial assessing the benefits of the use of durvalumab, a PD-L1 antibody, with and after concurrent chemoradiotherapy for locally advanced cervical cancer.1 Results from the CALLA study have been highly awaited by gynecological oncologists worldwide. We have analysed the results with keen interest and would like to congratulate the authors for their hard work in this landmark trial. In the intent-to-treat population, the progression-free survival was not significantly different between the durvalumab plus concurrent chemoradiotherapy group and the concurrent chemoradiotherapy group (hazard ratio [HR] 0·84; 95% CI 0·65–1·08; p=0·17).